US Patent Issued to New York University on June 24 for "Therapeutic targeting of KMT2D mutant lung squamous cell carcinoma through RTK-RAS signaling inhibition" (New York, Massachusetts Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,336,988, issued on June 24, was assigned to New York University (New York).

"Therapeutic targeting of KMT2D mutant lung squamous cell carcinoma through RTK-RAS signaling inhibition" was invented by Kwok-Kin Wong (Arlington, Mass.), Yuanwang Pan (New York), Han Han (New York) and Hua Zhang (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided is a method for treatment of lung squamous cell carcinoma (LUSC) by administering to an individual in need of treatment one or more inhibitors of the RTK-Ras signaling pathway. The LUSC cells may carry a mutation in a KMT2D gene. The inhibitors of the RTK-Ras signaling pathway are SHP2 inhibitors or epid...